BR112018074966A2 - anticorpos antagonísticos anti-molécula de orientação repulsiva a (grma) para tratar lesão na medula espinhal e dor - Google Patents
anticorpos antagonísticos anti-molécula de orientação repulsiva a (grma) para tratar lesão na medula espinhal e dorInfo
- Publication number
- BR112018074966A2 BR112018074966A2 BR112018074966-4A BR112018074966A BR112018074966A2 BR 112018074966 A2 BR112018074966 A2 BR 112018074966A2 BR 112018074966 A BR112018074966 A BR 112018074966A BR 112018074966 A2 BR112018074966 A2 BR 112018074966A2
- Authority
- BR
- Brazil
- Prior art keywords
- spinal cord
- cord injury
- pain
- gum
- treat spinal
- Prior art date
Links
- 208000020431 spinal cord injury Diseases 0.000 title abstract 3
- 206010072005 Spinal pain Diseases 0.000 title 1
- 230000003042 antagnostic effect Effects 0.000 title 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 230000003376 axonal effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- 230000008929 regeneration Effects 0.000 abstract 1
- 238000011069 regeneration method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
são revelados anticorpos anti-rgma e métodos para usar esses anticorpos para tratar lesão da medula espinhal, incluindo promover regeneração axonal, recuperação funcional ou ambas e para tratar dor, incluindo dor neuropática que surge a partir da lesão da medula espinhal.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662344233P | 2016-06-01 | 2016-06-01 | |
US62/344,233 | 2016-06-01 | ||
PCT/US2017/035183 WO2017210278A1 (en) | 2016-06-01 | 2017-05-31 | Anti-repulsive guidance molecule a (rgma) antagonistic antibodies for treating spinal cord injury and pain |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018074966A2 true BR112018074966A2 (pt) | 2019-03-12 |
Family
ID=59078172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018074966-4A BR112018074966A2 (pt) | 2016-06-01 | 2017-05-31 | anticorpos antagonísticos anti-molécula de orientação repulsiva a (grma) para tratar lesão na medula espinhal e dor |
Country Status (10)
Country | Link |
---|---|
US (3) | US20170349653A1 (pt) |
EP (1) | EP3464372A1 (pt) |
JP (2) | JP2019517480A (pt) |
CN (1) | CN109496218A (pt) |
AU (1) | AU2017273522A1 (pt) |
BR (1) | BR112018074966A2 (pt) |
CA (1) | CA3025329A1 (pt) |
MX (1) | MX2018014920A (pt) |
TW (1) | TW201803900A (pt) |
WO (1) | WO2017210278A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210032412A (ko) * | 2018-07-10 | 2021-03-24 | 미쓰비시 타나베 파마 코퍼레이션 | 말초신경장애, 또는 말초신경장애 혹은 성상세포장애가 인정되는 질환에 따른 동통의 예방 또는 치료 방법 |
AU2019306721A1 (en) * | 2018-07-19 | 2021-03-11 | St. Marianna University School Of Medicine | Therapeutic or prophylactic agent for HTLV-1-associated myelopathy (HAM), and method for treating HAM |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
JPH06507404A (ja) | 1991-05-01 | 1994-08-25 | ヘンリー エム.ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン | 感染性の呼吸性疾患の治療方法 |
US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
US6127977A (en) | 1996-11-08 | 2000-10-03 | Cohen; Nathan | Microstrip patch antenna with fractal structure |
ATE508733T1 (de) | 1996-03-04 | 2011-05-15 | Penn State Res Found | Materialien und verfahren zur steigerung der zellulären internalisierung |
US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
ES2236832T3 (es) | 1997-01-16 | 2005-07-16 | Massachusetts Institute Of Technology | Preparacion de particulas para inhalacion. |
AU747231B2 (en) | 1998-06-24 | 2002-05-09 | Alkermes, Inc. | Large porous particles emitted from an inhaler |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
TWI373343B (en) | 2000-02-10 | 2012-10-01 | Abbott Gmbh & Co Kg | Antibodies that bind human interleukin-18 and methods of making and using |
EP2042518A3 (en) | 2000-06-29 | 2009-04-08 | Abbott Laboratories | Dual specificity antibodies and methods of making and using |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
SG177008A1 (en) | 2003-03-05 | 2012-01-30 | Halozyme Inc | Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
JP2007510738A (ja) * | 2003-11-06 | 2007-04-26 | アイコス、コーポレーション | CD11d(α−d)インテグリンに特異的に結合する組成物を使用した慢性疼痛を処置する方法 |
EP1928506A4 (en) | 2005-08-19 | 2009-10-21 | Abbott Lab | IMMUNOGLOBULIN HAVING TWO VARIABLE DOMAINS AND USES THEREOF |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
ES2331448B1 (es) * | 2008-06-25 | 2010-10-18 | Fundacion Del Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion | Complejos de albumina con acidos grasos monoinsaturados omega-9 para el tratamiento de lesiones medulares. |
PL2807192T3 (pl) | 2012-01-27 | 2019-02-28 | Abbvie Deutschland | Kompozycja oraz sposób diagnostyki i leczenia chorób związanych ze zwyrodnieniem neurytów |
AU2013355324A1 (en) * | 2012-12-04 | 2015-05-21 | Abbvie Inc. | Blood-brain barrier (BBB) penetrating dual specific binding proteins |
-
2017
- 2017-05-31 AU AU2017273522A patent/AU2017273522A1/en active Pending
- 2017-05-31 CN CN201780046786.2A patent/CN109496218A/zh active Pending
- 2017-05-31 CA CA3025329A patent/CA3025329A1/en active Pending
- 2017-05-31 BR BR112018074966-4A patent/BR112018074966A2/pt unknown
- 2017-05-31 US US15/609,703 patent/US20170349653A1/en not_active Abandoned
- 2017-05-31 MX MX2018014920A patent/MX2018014920A/es unknown
- 2017-05-31 WO PCT/US2017/035183 patent/WO2017210278A1/en unknown
- 2017-05-31 JP JP2018562154A patent/JP2019517480A/ja active Pending
- 2017-05-31 EP EP17731343.4A patent/EP3464372A1/en active Pending
- 2017-05-31 TW TW106117998A patent/TW201803900A/zh unknown
-
2019
- 2019-12-11 US US16/710,757 patent/US20200347123A1/en not_active Abandoned
-
2021
- 2021-03-09 US US17/196,425 patent/US20220025031A1/en not_active Abandoned
-
2022
- 2022-04-06 JP JP2022063284A patent/JP2022091967A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20170349653A1 (en) | 2017-12-07 |
US20220025031A1 (en) | 2022-01-27 |
EP3464372A1 (en) | 2019-04-10 |
AU2017273522A1 (en) | 2018-12-06 |
WO2017210278A1 (en) | 2017-12-07 |
JP2019517480A (ja) | 2019-06-24 |
US20200347123A1 (en) | 2020-11-05 |
JP2022091967A (ja) | 2022-06-21 |
TW201803900A (zh) | 2018-02-01 |
CA3025329A1 (en) | 2017-12-07 |
MX2018014920A (es) | 2019-08-26 |
CN109496218A (zh) | 2019-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201991862A1 (ru) | Композиции и способы, предназначенные для лечения гемоглобинопатий | |
NZ734714A (en) | Methods of purifying cannabinoids, compositions and kits thereof | |
EA201792649A1 (ru) | Способы кондиционирования пациентов для t-клеточной терапии | |
DE112017000012A5 (de) | Finger-bewegungsschiene, halterung hierfür sowie dieses umfassendes therapiegerät und betriebsverfahren | |
BR112017024929A2 (pt) | conjugados de oligonucleotídeo-peptídeo | |
BR112015023349A2 (pt) | composto, composição farmacêutica, e, método de tratamento de uma doença, condição de saúde ou distúrbio | |
BR112014021104A2 (pt) | métodos e composições para o tratamento da doença de huntington | |
BR112018004680A2 (pt) | método de tratamento de distúrbios de desenvolvimento | |
BR112016018170A2 (pt) | métodos para tratar doença de alzheimer | |
BR112016015399A2 (pt) | método, método de tratamento de um sujeito, método de melhorar a eficácia da terapia do câncer, método para tratamento do câncer, método de tratamento de um câncer e método de definição de uma assinatura de resposta para uma terapia de modulador do ponto de checagem imunológico | |
BR112012005860A2 (pt) | peptídeos isolados do veneno de aranha, e usos dos mesmos | |
WO2016183532A8 (en) | Bacteria engineered to treat a disease or disorder | |
CO2018004684A2 (es) | Métodos para tratar la epilepsia | |
MX2020002762A (es) | Composiciones y métodos para tratar una lesión cerebral. | |
MX2019005165A (es) | Compuestos polimericos que liberan sulfuro de hidrogeno. | |
MX2017006609A (es) | Aditivo de nanocristales de celulosa o nanofibrillas de celulosa modificadas de forma quimica. | |
MX2016004837A (es) | Formulaciones de solventes hibridos para la remocion total de azufre organico y la remocion de gas acido total. | |
AR102062A1 (es) | Proceso para la separación mejorada de etilbenceno | |
BR112018074966A2 (pt) | anticorpos antagonísticos anti-molécula de orientação repulsiva a (grma) para tratar lesão na medula espinhal e dor | |
BR112017002629A2 (pt) | decoys de oligonucleotídeo para o tratamento de dor | |
BR112015029304A2 (pt) | processo integrado para tratamento de dissulfetos de dialquila | |
EA201891419A1 (ru) | Пептид-олигонуклеотидные конъюгаты | |
BR112015023260A2 (pt) | método de tratamento de grão com ozônio | |
BR112014025740A2 (pt) | vacinas e métodos para tratar a doença de lyme em cães | |
PH12017501872A1 (en) | Methods of treating diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |